造口还纳术中预防性生物补片植入的长期成本效益:ROCSS随机对照试验5-8年随访
ROCSS-Ex研究对ROCSS试验存活队列进行5-8年随访,评估造口还纳术中预防性生物补片的长期成本效益。598例可随访患者中396例有HerQLes评分,两组腹壁特异性生活质量无差异(均值差1.48,95%CI -2.35至5.32,P=0.45),全队列长期无成本获益。但补片组术后3年内造口部位并发症更少且再干预更少(32 vs 54,发生率比0.55,95%CI 0.31-0.97,P=0.04)。
要点
- 预防性生物补片未改善5-8年腹壁特异性生活质量
- 全队列长期无成本获益,不支持常规使用
- 补片组3年内造口部位并发症及再干预显著减少
核心结论
- 预防性生物补片与标准修补在术后5-8年腹壁特异性生活质量上结局相当。
- 全队列长期无成本获益,但补片组早期并发症和再干预更少。
研究设计与样本
- ROCSS-Ex为ROCSS随机对照试验的长期随访研究,纳入英国原中心符合条件的存活参与者。
- 原ROCSS试验共790例患者,598例可长期随访,396例有HerQLes评分(无补片191例,补片205例)。
- 主要结局为腹壁特异性生活质量,采用HerQLes评分和EQ-5D-5L测量,评估者对原始分组设盲。
主要发现
- 两组主要结局无差异:均值差1.48,95%CI -2.35至5.32,P=0.45。
- 全队列长期无常规预防性生物补片植入的成本获益。
- 补片组术后3年内造口部位并发症显著更少,再干预需求更少(32 vs 54,发生率比0.55,95%CI 0.31-0.97,P=0.04)。
临床怎么用
- 不支持在造口还纳术中常规植入预防性生物补片。
- 对早期再干预风险高的患者,可考虑预防性补片以减少术后3年内并发症和再手术。
局限性
- 长期随访仅纳入存活队列,可能存在选择偏倚。
- HerQLes评分仅覆盖396/598例可随访患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The original ROCSS trial demonstrated a significant reduction in clinically detectable incisional hernias at 2 years in patients receiving prophylactic biological mesh during stoma closure. ROCSS-Ex was designed to investigate the 5-8-year cost-effectiveness of mesh in the surviving cohort using an abdominal wall-specific quality of life score. METHODS: Eligible participants from original UK centres were identified. The primary outcome (abdominal wall-specific quality of life) was measured using the HerQLes score and EQ-5D-5L. Assessors remained blind to patients' original allocation, even if the patient was aware of their treatment. RESULTS: Of the original 790 patients, 598 were available for long-term follow-up. HerQLes scores were available for 396 patients (no mesh: 191, mesh: 205). There was no difference in primary outcome between the two groups (mean difference of 1.48, 95% c.i. (-2.35, 5.32), P = 0.45) and no cost benefit of routine insertion of prophylactic biological mesh across the entire cohort in the long term. However, patients who received mesh experienced significantly fewer stoma site complications within the first 3 years after reversal and needed fewer surgical reinterventions (32 versus 54 for the no mesh group; incidence rate ratio of 0.55, 95% c.i. (0.31, 0.97), P = 0.04). CONCLUSIONS: ROCSS-Ex has shown equivocal outcomes for prophylactic mesh insertion versus standard repair on abdominal wall-specific quality of life 5-8 years after surgery. As most reinterventions occurred within the first 3 years post-surgery, there may be a role for prophylactic mesh in a subset of patients who would be most adversely affected by repeated surgery early on. TRIAL REGISTRATION: ISRCTN25584182 (http://www.clinicaltrials.gov).
引用
- Long-term cost-effectiveness of insertion of a biological mesh during stoma-site closure: 5-8-year follow-up of the ROCSS randomized controlled trial. Br J Surg. 2024. PMID: 39129618. doi:10.1093/bjs/znae159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。